DANZITEN vs HYFTOR

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 16, 2026·How we rate

Possible drug interaction. DANZITEN and HYFTOR are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	DANZITEN	HYFTOR
Rating	70/100	New
Pharmacy pays	—	~$48.61 /30
Type	RX	RX
Active ingredient	NILOTINIB TARTRATE	SIROLIMUS
Manufacturer	Azurity	Nobelpharma
Dosage forms	Tablet	Topical
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	None
Treats	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors	Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

danziten hyftor

Rating

70/100

New

Pharmacy pays

—

~$48.61 /30

Type

Active ingredient

NILOTINIB TARTRATE

SIROLIMUS

Manufacturer

Azurity

Nobelpharma

Dosage forms

Tablet

Topical

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors

Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

Frequently asked questions

What is the difference between Danziten and Hyftor?

Danziten contains Nilotinib Tartrate, while Hyftor contains Sirolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.